NCT05288673 - A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2015

Primary Completion Date

September 1, 2016

Study Completion Date

September 1, 2016

Conditions

Healthy

Interventions

DRUG

ALXN1210

ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.

DRUG

Placebo

Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).

Trial Locations (1)

Unknown

Clinical Trial Site, London